Erbulozole (R55104) is a congener of the microtubule inhibitor tubulozole. It is undergoing phase I clinical trials as a chemotherapeutic agent.[1]

Erbulozole
Clinical data
Other namesErbuzole
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC24H27N3O5S
Molar mass469.56 g·mol−1
3D model (JSmol)
  • CCOC(=O)NC1=CC=C(C=C1)SC[C@H]2CO[C@](O2)(CN3C=CN=C3)C4=CC=C(C=C4)OC
  • InChI=1S/C24H27N3O5S/c1-3-30-23(28)26-19-6-10-22(11-7-19)33-15-21-14-31-24(32-21,16-27-13-12-25-17-27)18-4-8-20(29-2)9-5-18/h4-13,17,21H,3,14-16H2,1-2H3,(H,26,28)/t21-,24+/m1/s1
  • Key:KLEPCGBEXOCIGS-QPPBQGQZSA-N
  (verify)

Synthesis

edit
 
Erbulozole synthesis: Lednicer book 6 (Drugs of the Future citation).

References

edit
  1. ^ Van Belle SJ, Distelmans W, Vandebroek J, Bruynseels J, Van Ginckel R, Storme GA (1993). "Phase I trial of erbulozole (R55104)". Anticancer Research. 13 (6B): 2389–91. PMID 8135472.

Other reading

edit
  • Distelmans W, VanGinckel P, Heeres J, Van der Veken LJ (1991). "Erbulozole. Antineoplastic, Microtubule inhibitor". Drugs Future. 16 (6): 577.